Intimation for alteration in Memorandum of Association (MOA) of Company

The Board of Directors of Titan Biotech Ltd, at its meeting on November 29, 2025, approved a sub-division/split of equity shares in the ratio of 1:5 — one equity share of face value Rs. 10 will be split into five equity shares of face value Rs. 2 each. As a result, the issued and paid-up share capital will increase from 82,63,700 shares to 4,13,18,500 shares, while the total share value remains unchanged. The company stated the rationale is to enhance liquidity and make shares more affordable for retail investors. The split is subject to shareholder approval via postal ballot and other regulatory approvals, with completion expected within two months of member approval. The record date will be announced later.